News >

Enzalutamide Shows Early Promise in AR-Positive TNBC

Jason Harris
Published: Tuesday, Jan 30, 2018

Tiffany A. Traina, MD

Tiffany A. Traina, MD
Enzalutamide (Xtandi) demonstrated early signs of efficacy in patients with androgen receptor (AR)-positive triple-negative breast cancer (TNBC), according to findings from the phase II MDV3100-11 study published in the Journal of Clinical Oncology.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication